ATXI — Avenue Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.27m
- -$0.67m
- $1.40m
Fortress Biotech shares plunge after highly dilutive offering
Brief: Avenue Therapeutics Announces Pricing Of $5.0 Million Public Offering
Avenue Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Avenue Therapeutics Inc Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Avenue Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Avenue Therapeutics Q2 EPS USD -0.52
Avenue Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: Avenue Therapeutics Says First Patient Dosed In Phase 1B/2A Trial Of AJ201
Brief: Avenue Therapeutics Announces Agreement With The FDA On Phase 3 Study Design For IV Tramadol
Brief: Avenue Therapeutics Says On July 17 Nasdaq Granted Co's Request For Extension Of Deadline To Regain Compliance With Listing Rule To November 15
Brief: Avenue Therapeutics Files For Shelf Of Up To 1.1 Mln Shares
Brief: Avenue Therapeutics Received Deficiency Letter From Nasdaq Stock Market
Brief: Avenue Therapeutics Reports Q1 2023 Financial Results
U.S. STOCKS ON THE MOVE-Nvidia, Nuvei, Boeing
U.S. STOCKS ON THE MOVE-SAB Biotherapeutics, Blue Star Foods, Bellus Health
U.S. STOCKS ON THE MOVE-Johnson & Johnson, U.S. banks, Lockheed Martin
U.S. STOCKS ON THE MOVE-Bellus Health, Gamida Cell, Avenue Therapeutics
Avenue Therapeutics rises on positive FDA meeting for proposed study
Brief: Avenue Therapeutics Announces Regulatory Update Based On Type C Meeting With FDA